A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
← catalyst calendarSponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
222actual
Sites
58
Countries
Canada, Czechia, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-25 | actual | When the study began enrolling |
| Primary completion | 2025-07-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-18 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Drug: LY4100511
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)
measured Week 12
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-03-18 · 1.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-06-20 · 968 KB · SAP_001.pdf
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed